Otsuka Pharmaceutical Companies (U.S.) dans l'actualité
Développement et commercialisation pharmaceutiques
Tamtam a trouvé 16 articles récents sur Otsuka Pharmaceutical Companies (U.S.).
- (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
- Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Otsuka Pharmaceutical to acquire Transcend Therapeutics in $700M deal
- Otsuka Pharmaceutical to Acquire Transcend Therapeutics
- Leading in the Psychedelic Space: Q&A with Tarek Rabah
- Japanese Pharmas Looking Beyond Borders for M&A to US, EU
- FDA approves Otsuka kidney disease therapy
- US FDA approves Otsuka's drug for a type of kidney disease
- Otsuka Pharmaceutical acquires Cantargia's CAN10 program in a deal worth over $600 million
- Otsuka Pharmaceutical acquires Cantargia's CAN10 program in a deal worth over USD 600 million
- Lupin shares gain 4% on Tolvaptan Tablets launch in US; details here
- Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products｜May 9, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- CEO of Otsuka North America: Are We Getting better access with AI?
- Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement
- Otsuka Pharmaceutical Companies US Welcomes Jane Urban as VP of Customer Engagement Operations
- Schizophrenia Drugs Market Size | Industry Report, 2030
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Otsuka Pharmaceutical Companies (U.S.) ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires